Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
May 2024 in “JAMA Dermatology” Oral contraceptive use may increase the risk of frontal fibrosing alopecia in women with a specific CYP1B1 gene variant.
15 citations
,
May 2009 in “Steroids” Certain compounds reduced hamster flank organ size by inhibiting 5α-reductase, like finasteride, without affecting androgen receptors.
March 2014 in “Journal of The American Academy of Dermatology” Azathioprine may be an effective treatment for severe hair loss.
15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
8 citations
,
March 2008 in “Deutsche medizinische Wochenschrift/Deutsche Medizinische Wochenschrift” Adding estrogen increased bone mass in a transsexual man undergoing hormone therapy.
October 2024 in “Journal of the Endocrine Society” Gender-affirming hormone therapy affects metabolism differently based on treatment type.
9 citations
,
April 2011 in “PubMed” Spironolactone is used in dermatology to treat skin conditions related to hormones, but is not safe for pregnant women or men.
11 citations
,
January 1985 in “Archives of Dermatology” Topical antiandrogens might treat skin issues like hair growth, balding, and acne, but finding effective treatments without side effects is challenging.
January 2019 in “Dermatologica Sinica” Dutasteride improved both hair loss and acne in two young men.
17 citations
,
January 1995 in “The American Journal of Medicine” The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.
49 citations
,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
39 citations
,
August 2004 in “International journal of gynaecology and obstetrics” Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
26 citations
,
January 2014 in “ALTEX” Pesticides can cause reproductive and adrenal health issues.
1 citations
,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
February 1999 in “Analytical Sciences” A new antiandrogen compound was made and its detailed three-dimensional shape was described.
January 2023 in “Seven Editora eBooks” A rare ovarian tumor was diagnosed in a woman from North Brazil, and surgery is the preferred treatment.
10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
3 citations
,
July 2019 in “Case Reports in Obstetrics and Gynecology” A young woman's rare ovarian tumor was successfully removed, improving her hormonal symptoms.
6 citations
,
January 1984 in “PubMed” Spironolactone treatment reduced hair growth and androgen levels in hirsute women, but the overall effectiveness was just adequate.
July 2020 in “Zenodo (CERN European Organization for Nuclear Research)” Pioglitazone combined with metformin or spironolactone improves PCOS symptoms and insulin resistance.
July 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Hirsutism treatment should focus more on patient needs and quality of life.
11 citations
,
January 2014 in “CellBio” Sex steroids, especially progesterone, can slow down the growth of mouse melanoma cells.
4 citations
,
January 1998 in “Heterocycles” Researchers made two new compounds that could be used for medicine.
1 citations
,
March 1991 in “PubMed”
June 2003 in “Obstetrical & Gynecological Survey” After chemotherapy for a gestational trophoblastic tumor, normal pregnancy rates are possible, but there's a slightly higher risk of the tumor reoccurring in future pregnancies.